Lipella Pharmaceuticals Inc. Common Stock Cash Flow Conversion Efficiency
Lipella Pharmaceuticals Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Lipella Pharmaceuticals Inc. Common Stock (LIPO) has a cash flow conversion efficiency ratio of -1584.949x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.36 Billion) by net assets ($1.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lipella Pharmaceuticals Inc. Common Stock (2019–2024)
Cash flow conversion efficiency of Lipella Pharmaceuticals Inc. Common Stock from 2019 to 2024. This chart illustrates how Lipella Pharmaceuticals Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Lipella Pharmaceuticals Inc. Common Stoc stock price for real-time trading data and today's change.
Lipella Pharmaceuticals Inc. Common Stock Cash Flow Conversion Ratio Explained
Lipella Pharmaceuticals Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lipella Pharmaceuticals Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lipella Pharmaceuticals Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Lipella Pharmaceuticals Inc. Common Stoc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Black Bear Minerals Limited
AU:BKB
|
N/A |
|
S&W Seed Company
NASDAQ:SANW
|
-0.159x |
|
FlexShopper Inc
NASDAQ:FPAY
|
-0.337x |
|
Conn's, Inc.
NASDAQ:CONNQ
|
-0.118x |
|
SOL GLOBAL INVESTM. CORP
F:9SB
|
0.233x |
|
Binh Duong Construction & Civil Engineering JSC
VN:BCE
|
N/A |
|
SDM SE INH O.N.
F:75S
|
N/A |
|
SDM SE
XETRA:75S
|
0.321x |
Annual Cash Flow Conversion Efficiency for Lipella Pharmaceuticals Inc. Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Lipella Pharmaceuticals Inc. Common Stock from 2019 to 2024. Review LIPO free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.92 Million | $-3.95 Million | -2.058x | -105.45% |
| 2023-12-31 | $3.14 Million | $-3.15 Million | -1.002x | -155.80% |
| 2022-12-31 | $4.68 Million | $-1.83 Million | -0.392x | +43.64% |
| 2021-12-31 | $1.42 Million | $-989.27K | -0.695x | -1026.69% |
| 2020-12-31 | $463.32K | $-28.58K | -0.062x | -118.66% |
| 2019-12-31 | $-118.34K | $-39.12K | 0.331x | -- |
About Lipella Pharmaceuticals Inc. Common Stock
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen plan… Read more